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Early detection of cancer can significantly reduce mortality and improve the quality of life of
persons with cancer. In this article we describe the three national screening programmes that
have been introduced in Malta since 2009 and that are based on guidelines supported by the
European Commission. Screening for breast cancer was the first national screening programme
implemented in Malta. After several years of roll-out and gradual expansion of the service, this
programme is now reaching the targets of the European Commission on Breast Cancer (ECIBC)
Guideline Group in terms of target population and screening frequency. Colorectal Cancer (CRC)
Screening was the second programme to be introduced in 2013 while Cervical Cancer Screening
was launched in 2016. These programmes are being gradually scaled up, and there is
continuous investment in new technologies and human resources. Low participation rates
remain a challenge, however improvements have been achieved following awareness campaigns
and evaluation of the invitation protocols.
ABSTRACT
CANCER SCREENING
Background
 
Cancer is a ‘fierce’ public health enemy. Every year it is attributed
as the main cause of death for around 30% of all mortality in
Malta. Nearly half of cancer deaths can be avoided with more
preventive action to address and allay risks. Reducing the
incidence of cancer by tackling major life-style determinants, such
as smoking, nutrition and physical activity, is a major objective of
public health work. Another important and effective prevention
tool is screening for cancer. 
 
Regular and systematic examinations can detect the disease
early, when it is more responsive to less aggressive treatment. If
followed by appropriate care, these examinations can
significantly reduce cancer mortality and improve the quality of
life of cancer patients.
 
Screening refers to the use of relatively simple tests across an
apparently healthy population in order to identify individuals who
have risk factors or an unrecognized disease or defect. World
Health Organisation (WHO) criteria specify that a screening test is
not intended to be diagnostic, and persons with a positive or
suspicious finding must be referred for a confirming diagnosis
and necessary treatment[1]. It is essential that screening
identifies those who are more likely to be helped than harmed by
further tests or treatment to reduce the risk of a disease or its
complications[2].
 
In 2003, the Council of the European Union, in accordance with
the WHO criteria, recommended cancer screening with a
systematically organised population-based approach and quality
assurance at all appropriate levels[3]. Screening programmes
were recommended for breast, cervical and colorectal cancers in
agreement with evidence-based guidelines.
 
Organised cancer screening programmes in Malta
 
Screening represents an important public health function. All
three National Cancer Screening Programmes are guided by the
principle that if cancers are detected at an early stage or even in
the pre-cancerous stage, treatment will be less invasive, is more
likely to be successful and the survival rate is improved. 
 
As outlined in the European Code Against Cancer[4], regular
participation in Breast, Cervical and Colorectal Screening
Programmes is one of the ways to reduce both mortality as well
as cancer risk. Screening for colorectal cancer and cervical cancer
can identify precancerous stages that can be treated and stopped
from developing into cancer.
 
The introduction of a screening programme should follow only
after careful evaluation and cost benefit analysis. The publication
of guidelines supported by the European Commission has paved
the way considerably for the introduction and implementation of
the three National Cancer Screening Programmes. 
 
Screening programmes often feature highly on the political
agenda with the decision to introduce a screening programme
being subject to multiple pressures, including those from NGO’s,
cancer survivors and the general public. The first National
Screening Programme to be introduced in Malta was that of
Breast Cancer Screening launched towards the end of 2009. This
was a long-awaited electoral promise with the media also
drawing public attention to the fact that Malta was one of the 2 or
3 remaining EU countries not having such a programme in place. 
 
Breast Cancer Screening
 
The programme initially targeted women aged between 54 to 60
years who were called for regular screening with a three-year
interval cycle. Subsequently, the age group was expanded to
cover an increasing spectrum of cohorts. The European
Commission on Breast Cancer (ECIBC) Guideline Group5 strongly
recommends mammography screening for asymptomatic
women aged 50 to 69 years with an average risk of breast cancer.
Currently the Breast Screening Programme has reached this
target and offers mammography screening to all women aged
between 50 and 69 years. In addition, the screening interval has
been reduced from 3 years to a 2-year interval period, in keeping
with EU international guidelines.
 
From the 13,000 women who are screened each year, around 7%
are recalled for further investigations and under 1% of all women
screened are diagnosed with breast cancer. Till the end of 2018, a
total of 468 breast cancer cases have been diagnosed through
the Breast Screening Programme.
 
The question which is often raised is: how effective is routine
breast screening in reducing breast cancer mortality? In 2016 a
report was commissioned by the Agency for Healthcare Research
and Quality to review the 2009 US Preventive Services Taskforce
Recommendation[6]. This advised biennial mammography
screening for average risk women aged 50-74 years. 
 
The researchers concluded that mammography screening does
decrease mortality from breast cancer, with higher statistical
significance being seen in older age groups (50-69 years)
compared to the younger age groups. The number of deaths
prevented was highest in the 60 to 69-year age group, with 12-21
deaths being prevented per 10,000 women screened for 10 years
(Figure 1). Meta-analyses from recent reviews conducted by the
EUROSCREEN working Group indicated a 25-31% mortality
reduction for women aged 50-69 years. 
 
Mammography screening at any age is a trade-off between a
continuum of benefits and potential harms (through
overdiagnosis and radiation) that varies at population and
individual levels.
 
Over the past 10 years, there has been a slight reduction in the
mortality rate of breast cancer since the introduction of breast
cancer screening. The reason for this is unknown, but it could be
the result of a combination of factors, including screening and
earlier diagnosis, and the availability of new treatment options.
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Figure 1. Mortality Rate (EASR)* of breast cancer in the Maltese
Islands between 2007-2016
* EASR: age-standardized rates (per 100,000 women) using the
European standard population
Colorectal cancer screening
 
The second programme to be introduced was that for Colorectal
Cancer (CRC) Screening, which commenced a phased roll out in
2013. Both men and women aged 60-64 years were invited to
participate over a 2-year period. 
 
Colorectal cancer is a major public health problem in Malta, being
the second most commonly diagnosed cancer in both men and
women with approximately 253 new cases diagnosed in 2016[7].
Ninety-five percent of cases occur in people aged over 50 years.
 
 The aim of CRC screening is to lower the burden of CRC in the
population by discovering the disease in its early latent stages
where treatment is more effective than if diagnosis occurs in the
later stages. In addition, early treatment of invasive lesions, for
example by endoscopic resection, can be less detrimental for
quality of life. 
 
Screening also identifies precursor lesions and thus has a
prevention effect, with the endoscopic removal of premalignant
lesions reducing the incidence of CRC by avoiding the progression
to cancer. Since the introduction of the Colorectal Screening
Programme in 2013, the incidence of colorectal cancer has
increased, an average of incidence between 2013 – 2016 shows
275 cases per year, compared to an average incidence of 219
cases yearly picked up during the previous 4 years (Figure 2). 
 
A possible reason for this increase is that more cases are being
picked at an early stage because of repeated screening. To date,
the Colorectal Screening Programme has resulted in 133 cases of
colorectal cancer being detected.
The FIT also allows for changes in the designated ‘cut off’ point at
which a result is designated positive. By changing the ‘cut-off’
concentration, the proportion of false-positive tests and the
number of colonoscopies performed can be adjusted to meet
local requirements. Currently a 100ng/ml is used as the positive
cut-off point.
 
Cervical cancer screening
 
The last programme to be introduced was that of Cervical Cancer
Screening, which was launched in March 2016. Cancer of the
uterine cervix primarily affects younger women, with most cases
appearing between the ages of 35 and 50. Based on this, the
selected target group for screening included women aged 25-35,
with a 3-year screening interval.  
 
Cervical cytology is the current recommended standard test for
cervix screening. Liquid based cytology is used locally as a
method of testing. This is preferable to conventional cytology as
it is associated with a lower proportion of unsatisfactory samples
and ancillary testing, such as high-risk HPV testing in the case of
ASC-US (atypical squamous cells of undetermined significance),
can be performed on the same sample[11].
 
Cervical Cancer is one of the cancers which can be most effectiely
controlled by screening. Detection of cytological abnormalities
and subsequent treatment where abnormalities are high-grade,
avoids the development of cancer. The International Agency for
Research on Cancer (IARC) reports that cytology screening at
population level every 3-5 years can reduce cervical cancer
incidence up to 80%[12]. Until the end of 2018, over 7,200 Smear
Tests were carried out as part of the National Screening
Programme and 106 cases of low-grade squamous intra-
epithelial lesion (LSIL), 32 cases of high-grade squamous intra-
epithelial lesion (HSIL) and 4 cases of cervical cancer were
identified.
 
The participation rate in the Cervical Cancer National Programme
is low, with a 33% intention to participate amongst women
invited to take part in the programme. However, the results from
the European Health Interview Survey (EHIS) 2014/201513 are
more encouraging with 74% of women reporting having carried
out a cervical smear test at least once, whereas 50% report
having carried out the smear test in the last 3 years.
 
 This shows a consistent improvement in comparison to similar
EHIS reporting carried out in 2008 and 2002, where the number
of women who reported not having ever carried out a cervical
smear test where 37% and 41% respectively. Results from the
latest EHIS indicate that 81% of cervical screening is carried out in
the private sector.
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Figure 2. Incidence of colorectal cancer, Malta, 2007-2016
(source: DHIR)
There is sufficient evidence to indicate that invitation to CRC
Screening reduces mortality from CRC by 14-16%8,9. A similar
reduction in mortality was also reported by a systematic review
commissioned for the US Preventive Services Taskforce, where a
9-22% CRC mortality reduction was reported with biennial
screening after 2 to 9 rounds of screening and 11-30 years of
follow up[10].
 
The CRC Screening Programme has expanded substantially over
the years. Currently, screening through the Faecal
Immunochemical Test (FIT) is offered to all men and women aged
55–69 years with a two-year screening interval. Immunochemical
tests have improved test characteristics compared with
conventional Guaiac-based faecal occult blood tests. 
 
FIT is both analytically and clinically more sensitive and specific
for the detection of haemoglobin, so only a single test is required
without any change in diet prior to taking the test. 
Barriers to participation
 
Although people are now better informed and aware of various
cancer issues, healthy asymptomatic people are not always ready
to participate in Screening Programmes. During 2017 and 2018
the National Screening Centre took several actions to mitigate
non-responsiveness including the sending of reminder letters,
kits rather than invites being sent to previous participants as well
as aggressive awareness campaigns. As a result, an increase in
the participation rate was observed over the last 2-3 years from
45% to 54%.
 
In their national retrospective study carried out in 2015, Marmara
et al.14, reported that a variety of factors that render non-
attendees statistically significantly more likely. These included
women with a lower family income, widowers, non-drivers, not
having a breast, having no relatives or close friends with cancer,
and who were less encouraged by a physician, being unsure of
the screening frequency, more anxious and fearful. Perceived
benefits, barriers, cues to action, self-efficacy and emotional
representations were the most significant variables to describe
the differences between lifetime attendees and non-attendees.
Perceived barriers and cues to action were the strongest
predictors for lifetime non-attendance14. 
 
Similarly, Deguara M.15 in her 2016/7 survey on cervical cancer
awareness reported that those who attended for screening
regularly were more likely to be females with children or having
had a close family member with cancer. The main reasons for
nonattendance were embarrassment, fear of the test and fear of
a bad result.
 
Whilst it is important that persons are well informed and make
informed choices about participation in Screening Programmes,
Health Care Professionals have a pivotal role in the success of our
population-based Screening Programmes, empowering people to
take ownership of their health and overcome any unfounded
fears.
 
Conclusion
 
Over the past ten years Malta has introduced and operated three
significant organised programmes to deliver cancer screening
services to different groups of people in line with the European
Council recommendation and current scientific evidence on
efficacy, the balance between benefit and harm and cost-
effectiveness. Programmes started with a small age cohort and
are being gradually scaled up to included wider age ranges,
increased frequency (where applicable) and also upgraded
technology where indicated.
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Who is invited to participate
Table 1. Overview of Screening
Programmes in Malta, 2019  
 
* YOB: Year of Birth
